Clinicopathologic Features and Clinical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi-institutional Experience and Review of the Literature

Broadwater, Devin R.; Conant, Joanna L; Czuchlewski, David R.; Hall, Jordan; Wei, Shi; Siegal, Gene P.; Peker, Deniz

doi:10.1016/j.clml.2018.07.286

Cited by 5 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus HS can be classified as primary or secondary. In the case series of Brodwater et al, (N = 23) secondary HS presented with more aggressive behavior than de novo HS (11.8 months OS compared to 70 months, with a median difference of 58.2 months, p = 0.001) [9]. Although our case was characterized as de novo HS, its poor prognosis (OS 4 months) and marked clinical aggressiveness leads us to believe that disseminated primary bone involvement is a factor related to poor prognosis, similar to that observed in secondary HS cases.…”

Section: Discussionmentioning

confidence: 92%

“…In a recent study published in 2018, Brodwater et al described 23 cases of HS, isolated bone involvement was not described in any of these patients [9]. In the largest case series published to date comprising 159 cases of HS from several North American centers, primary bone involvement has not been described by the authors either.…”

Section: Discussionmentioning

confidence: 98%

“…HS is usually aggressive and present as advanced stages III and IV and with poor response to therapy, although exceptions have been reported. In fact, most patients die from disease progression [9]. Lymphadenopathy is common and most cases present extralymphonodal involvement, most commonly in the gastrointestinal tract, skin, superficial and deep soft tissues, lung and nasal cavity [10].…”

Section: Case Presentationmentioning

confidence: 99%

See 2 more Smart Citations

Primary Histiocytic Sarcoma of Bone with Disseminated Involvement - Initial Presentation Mimicking Multiple Myeloma: The Atypical Face of a Rare Neoplasm

Lage¹

2019

Ann Hematol Oncol

View full text Add to dashboard Cite

Histiocytic Sarcoma (HS) is an uncommon malignancy derived from macrophage/dendritic lineage cells and accounts for less than 1% of hematologic tumors. Due to its rarity, little is known about its clinical-biological behavior and therapeutic recommendations have not been standardized so far. In addition to lymph node enlargement most cases present extranodal involvement, especially in the gastrointestinal tract, skin and soft tissues. Bone involvement is usually described in association with systemic disease and in advanced stages. Here we describe a case of patient with HS with primary bone involvement and multiple osteolytic lesions and bone fractures in the absence of another organs involvement. A male patient presented with an aggressive disease with rapid progression and his disease was unresponsive to standard therapy. Although rare, this kind of HS presentation should fall within the scope of differential diagnosis of other neoplasms with widespread bone involvement such as multiple myeloma and bone metastasis from solid tumors as the prostate, breast and lungs.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 98%

Section: Case Presentationmentioning

confidence: 99%

See 1 more Smart Citation

Primary Histiocytic Sarcoma of Bone with Disseminated Involvement - Initial Presentation Mimicking Multiple Myeloma: The Atypical Face of a Rare Neoplasm

Lage¹

2019

Ann Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…Broadwater et al reported that the survival of patients with secondary HS was very poor, with a mean survival time of 11.8 months (12). In their report, all 6 patients with secondary HS (2 patients had history of hematological malignancy and 4 patients had a history of solid tumor) received chemotherapy or radiotherapy; thus, therapy-related HS is a possibility.…”

Section: Discussionmentioning

confidence: 96%

Successful Treatment of Incidental Histiocytic Sarcoma Concomitant with Laryngeal Carcinoma

2021

View full text Add to dashboard Cite

Histiocytic sarcoma (HS) is an extremely rare non-Langerhans cell disorder with an aggressive course and limited treatment options. HS most often presents at an advanced clinical stage, with a limited response to chemotherapy and high mortality. No standard treatment has been established for HS. We herein describe the first case of HS concomitant with laryngeal carcinoma that was promptly diagnosed and successfully treated; the condition of the patient has remained stable for 4 years with no recurrence.

show abstract

“…Klinicky se tyto histiocytární sarkomy chovají velmi agresivně, asi v 70 % je nemoc rozpoznána v generalizovaném stadiu (III a IV), a proto asi 60 % nemocných zemře v průběhu léčby na progresi nemoci. Medián přežití je pořád velmi krátký, jen 6 měsíců (45,46).…”

Section: Lokalizovaný Histiocytární Sarkomunclassified

Histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Comparison of recent WHO classification published 2017 and classification of Histiocyte Society published 2016

Král¹,

Adam²,

Ježová³

et al. 2020

Vnitr Lek

View full text Add to dashboard Cite

Interní hematoonkologická klinika LF MU a FN Brno, pracoviště Bohunice 2 Ústav patologie LF MU a FN Brno, pracoviště Bohunice Neoplazie z histiocytárních a dendritických buněk jsou velmi raritní, a tedy obtížně diagnostikovalné nemoci. Nejčastější z nich je histiocytóza z Langerhansových buněk, incidence ostatních nemocí je ještě menší. V následujícím přehledu je shrnuta jejich charakteristika a uvedeny recentní klasifikace, standardně používaná WHO klasifikace (poslední verze publikovaná v roce 2017) a paralelně s ní existující klasifikace, vytvořená společností Histiocyte Society (poslední verze publikovaná v roce 2016).Klíčová slova: neoplazie odvozené od histiocytárních a dendritických buněk. Histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Comparison of recent WHO classification published 2017 and classification of Histiocyte Society published 2016The histiocytoses are rare disorders characterized by the accumulation of cells thought to be derived from dendritic cells or macrophages. Their clinical behaviour ranges from mild to disseminated and, sometimes, life-threatening forms. The incidence of this diseases is much smaller, then the incidence of diseases derived from lymphocytic or myeloid lineage. Langerhans cell histiocytosis is most frequent disease from this group. The last version of WHO classification from 2017 and last version of classification published by Histiocyte Society is summarised in this paper.

show abstract

Clinicopathologic Features and Clinical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi-institutional Experience and Review of the Literature

Cited by 5 publications

References 32 publications

Primary Histiocytic Sarcoma of Bone with Disseminated Involvement - Initial Presentation Mimicking Multiple Myeloma: The Atypical Face of a Rare Neoplasm

Primary Histiocytic Sarcoma of Bone with Disseminated Involvement - Initial Presentation Mimicking Multiple Myeloma: The Atypical Face of a Rare Neoplasm

Successful Treatment of Incidental Histiocytic Sarcoma Concomitant with Laryngeal Carcinoma

Histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Comparison of recent WHO classification published 2017 and classification of Histiocyte Society published 2016

Contact Info

Product

Resources

About